Get in or Get Left Behind - Page 4 of 6

Get in or Get Left Behind

projected to reach $29.4 billion by 2011, up from $16.3 billion in 2006.



Further advances in surgical apparatuses and the discovery of safer and more flexible synthetic materials for implanted equipment are among the factors driving the growth in medical devices, according to Matthew Gardner, president and CEO of BayBio, a life science advocacy group in San Francisco.


“A lot of investment is going into high-reliability devices such as circuit boards and mainframes for medical devices that are not likely to be outsourced,” says Julian Harris, a research analyst with the consulting firm Frost & Sullivan in San Antonio. “These devices are found in minimally invasive surgery equipment and cardiovascular regulatory devices and have stricter quality standards.”


Gardner says that even in a bad economy, the development of new equipment remains resilient because product development takes a great deal longer than an economic cycle. And research funding from government agencies, such as the National Institutes of Health, that sustain medical research allows such development to continue on a positive growth curve. However, he adds that regulatory processes significantly prolong the time-to-market. “Diagnostic devices often enjoy faster returns on investment and less regulatory restrictions than devices for surgery or treatment,” Gardner says.


Mark Leahey, executive director of the Medical Device Manufacturers Association, says that considerable opportunities within the industry include clinical trials, distribution, and contract manufacturing for device components, especially miniaturized equipment.



By developing new or renewable sources of energy and raw materials, and by improving the efficiency of consumption, cleantech is answering a vast market opportunity, says Brian Fan, senior director of research at the Cleantech Group, a global cleantech industry research and consulting firm in San Francisco